Torrent Pharma.
Torrent Pharma. Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Semaglutide launch expected to be significantly larger than any previous product launches; initial sales projected between INR 200-250 crores in the first year, notably higher than Sitagliptin's INR 70-75 crores launch in 2023. FY27 India organic growth expected to be mid-teens %, driven by Semaglutide, chronic segment outperformance, and new launches (Page 7).
From Torrent Pharma.'s Q4 FY26 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Semaglutide launch expected to be significantly larger than any previous product launches; initial sales projected between INR 200-250 crores in the first year, notably higher than Sitagliptin's INR 70-75 crores launch in 2023.
- India base business (excluding JB) grew 15% in Q4 FY26, expected to deliver mid-teens growth in FY27, barring external demand shocks.
- Curatio business grew 27% in FY26, with strong outlook for continued traction driven by OTC advertising and field force expansion.
- Brazil market projected to grow 10-15% CAGR over FY26-27 driven by new launches and price increases.
- US business grew 31% INR growth in FY26, with expected single-digit growth on the back of single-digit product launches in FY27.
- JB Pharma salesforce attrition improved; integration expected to enhance revenue synergies over next 2-3 years.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Torrent Pharma. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Torrent Pharma plans to increase R&D spend by approximately 0.5% of sales in the upcoming year, largely allocated to India and the US markets, focusing on existing business lines (Page 13).
- There is interest in in-licensing products, especially from China and other markets, to expand opportunities in India (Page 6).
- For the Semaglutide injectable business in India, potential future manufacturing in-house is considered if the product scales significantly (Page 14).
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Torrent Pharma. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Torrent Pharma. — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹4.2K Cr, net profit ₹364 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Torrent Pharmaceuticals Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
- Morepen Laboratories Ltd (Q4 FY26)
472 crore, up 22% year-on-year (YoY) from Rs. Key concall takeaways from Morepen Laboratories Ltd's Q4 FY26 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY26)
202.12 Cr., a 2.50% increase quarter-on-quarter (Page 14) . Key concall takeaways from Anuh Pharma Ltd's Q4 FY26 earnings call — and how it ranks against…
- Themis Medicare Ltd (Q4 FY26)
Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8). Key concall takeaways from Themis Medicare Ltd's Q4 FY26 earnings call…
Frequently Asked Questions
What were Torrent Pharma. Q4 FY26 results?
Semaglutide launch expected to be significantly larger than any previous product launches; initial sales projected between INR 200-250 crores in the first year, notably higher than Sitagliptin's INR 70-75 crores launch in 2023. FY27 India organic growth expected to be mid-teens %, driven by Semaglutide, chronic segment outperformance, and new launches (Page 7).
What is Torrent Pharma. share price analysis?
Torrent Pharma. currently shows a neutral. The stock trades at a P/E of 83.5 with a market cap of ₹186,247 Cr. Investors should review the full earnings analysis for detailed insights.
Is Torrent Pharma. planning capital expenditure?
Torrent Pharma plans to increase R&D spend by approximately 0.5% of sales in the upcoming year, largely allocated to India and the US markets, focusing on existing business lines (Page 13).
Keep Torrent Pharma. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.